Actively Recruiting

All Genders
Healthy Volunteers
NCT04603404

Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF

Led by Chinese Academy of Medical Sciences, Fuwai Hospital · Updated on 2022-11-08

430

Participants Needed

1

Research Sites

621 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modal (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF derived from different causes.

CONDITIONS

Official Title

Multimodality Imaging in the Screening, Diagnosis and Risk StratifictiON of HFpEF

Who Can Participate

All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Left ventricular ejection fraction (LVEF) 50% or higher
  • N-terminal pro-b type natriuretic peptide (NT-proBNP) greater than 220 pg/ml or b type natriuretic peptide (BNP) greater than 80 pg/ml
  • Symptoms and syndromes of heart failure
  • At least one criterion of abnormal cardiac structure (left ventricular hypertrophy or left atrial enlargement) or function (based on tissue doppler or color doppler)
Not Eligible

You will not qualify if you...

  • Special types of cardiomyopathy, including hypertrophic cardiomyopathy and restrictive cardiomyopathy
  • Heart damage caused by infarction or ischemic cardiomyopathy and acute coronary syndrome
  • Severe arrhythmia
  • Severe primary cardiac valvular disease
  • Restrictive pericardial disease
  • Refusal to participate in the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fuwai Hospital

Beijing, Beijing Municipality, China, 100037

Actively Recruiting

Loading map...

Research Team

M

Minjie Lu, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here